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A B S T R A C T
Stanniocalcin 1 (STC1) and calcitonin gene-related peptide (CGRP) are involved in bone formation/
remodeling. Here we investigate the effects of STC1 on functional heterodimer complex CALCRL/
RAMP1, expression and activity during osteoblastogenesis. STC1 did not modify CALCRL and ramp1 gene
expression during osteoblastogenesis when compared to controls. However, plasma membrane spatial
distribution of CALCRL/RAMP1 was modiﬁed in 7-day pre-osteoblasts exposed to either CGRP or STC1,
and both peptides induced CALCRL and RAMP1 assembly. CGRP, but not STC1 stimulated cAMP accu-
mulation in 7-day osteoblasts and in CALCRL/RAMP1 transfected HEK293 cells. Furthermore, STC1 inhibited
forskolin stimulated cAMP accumulation of HEK293 cells, but not in CALCRL/RAMP1 transfected HEK293
cells. However, STC1 inhibited cAMP accumulation in calcitonin receptor (CTR) HEK293 transfected cells
stimulated by calcitonin. In conclusion, STC1 signals through inhibitory G-protein modulates CGRP re-
ceptor spatial localization during osteoblastogenesis and may function as a regulatory factor interacting
with calcitonin peptide members during bone formation.
© 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
In vertebrates, bone homeostasis is a dynamic process which in-
cludes a balanced calcium and phosphate metabolism, essential to
maintain a healthy bone mass. Bone formation and remodeling rely
on coordinated functions of bone forming (osteoblasts), resident
(osteocytes) and resorbing cells (osteoclasts) that are regulated by
several local and endocrine factors that act on calcium and phos-
phate homeostasis (Bellido et al., 2013; Henriksen et al., 2009;
Nakahama, 2010; Stenbeck et al., 2012). Most of these calciotropic
hormones mediate their action on osteoblasts regulating the os-
teoclastic differentiation and activity (Cao, 2011; Costa et al., 2011;
Kohli and Kohli, 2011; Naot and Cornish, 2008; Stenbeck et al., 2012).
Stanniocalcin 1 (STC1) is a glycosylated 50 kDa disulﬁde-
linked homodimeric protein (Trindade et al., 2009) that not only acts
on bone metabolism, but also is highly abundant in other tissues
such as kidney, heart, ovary and brain (Basini et al., 2010; Jiang et al.,
2000;Westberg et al., 2007;Worthington et al., 1999; Yoshiko et al.,
2002). During embryonic development, STC1 is highly expressed in
muscular and skeletal tissues, exhibiting calciotropic effects on os-
teogenesis by stimulating themajor constituents of themineral phase
of bone (Jiang et al., 2000; Stasko andWagner, 2001;Wu et al., 2006;
Yoshiko et al., 2002). The STC1 calciotropic effect is associated with
osteoblastic differentiation (Johnston et al., 2010; Yeung et al., 2012;
Yoshiko and Aubin, 2004; Yoshiko et al., 2003) and chondrogenic
growth inhibition (Wu et al., 2006). Moreover, transgenic studies
on mice have shown that human (h) STC1 ectopic expression de-
creases bone length (Varghese et al., 2002) leading to dwarﬁsm
(Filvaroff et al., 2002). The STC1 induced-delay in bone develop-
ment is associated with its effect on the regulation of growth plate
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chondrogenesis, acting as a paracrine/autocrine growth factor (Wu
et al., 2006). Furthermore, STC1 is also involved in angiogenesis
(He et al., 2011). Recently, both STC1mRNA and protein were shown
to be up-regulated during synovial membrane inﬂammation in pa-
tients with osteoarthritis and was considered to be a key mediator
of synovium neovascularization in osteoarthritis synovitis (Lambert
et al., 2014).
Similar to STC, the calcitonin (CT) family members, a group of
small peptide hormones, are also involved in calcium homeosta-
sis, vertebrate osteogenesis and osteoblast function (Naot and
Cornish, 2008). CT members share moderate sequence similarity but
their secondary structures are strongly correlated. They are char-
acterized by the presence of two conserved cysteine residue positions
that form a ring structure at the N-terminus crucial for biological
activity and receptor activation (Feyen et al., 1992; Naot and Cornish,
2008; Pozvek et al., 1997). In mammals, six CT family member pep-
tides have been identiﬁed, which include calcitonin gene-related
peptide alpha and beta (αCGRP and βCGRP), amylin (AMY),
adrenomedullin 1 (ADM1), adrenomedullin 2 (ADM2 or interme-
din) and calcitonin receptor-stimulating peptide (CRSP) (Granholm
et al., 2011; Naot and Cornish, 2008) with distinct effects on bone
cells.
Calcitonin gene-related peptide (CGRP) is a small neuroendo-
crine peptide (Amara et al., 1982; Goodman and Iversen, 1986) that,
similar to STC1, has an important role in osteogenesis and osteo-
blast activity. CGRP is abundantly expressed in skeletal sensory
neurons and is involved on bone formation and inhibition of bone
resorption (Granholm et al., 2011; Schinke et al., 2004; Villa et al.,
2006; Wang et al., 2010). Similar to CT, and different from ADM1,
the members of this peptide family have a predominant anabolic
action and inhibit bone resorption and osteoclast formation
(Granholm et al., 2011; Naot and Cornish, 2008; Wang et al., 2010).
In mammals, CGRP immunoreactivity is detected in bone tissue –
in the periosteum, bonemarrow and the epiphyseal trabecular bone,
and the presence of CGRP in osteoblast cultures was found to in-
crease cell proliferation and the synthesis of cytokines, growth
factors, and collagen (Chang and Hsu, 2013; Vignery and McCarthy,
1996; Villa et al., 2006). An important stimulatory effect of CGRP
during early stages of the osteoblastic differentiation has been also
reported (Kawase et al., 2003; Wang et al., 2010). The receptor for
CT (CTR) is also detected in osteoblasts. However the effect of CT
in osteoblasts bone formation is not consensual (Monier-Faugere
et al., 1996; Villa et al., 2003).
CGRP activates a speciﬁc receptor, CALCRL, a member of the class
2 B1 GPCR family which forms a dimer complex with a transmem-
brane accessory protein, the receptor activity-modifying protein 1
(RAMP1) (Born et al., 2002; Conner et al., 2002). CALCRL and RAMP1
have been detected in pre- and mature osteoblasts and, in the
presence of CGRP, the protein complex signals via an increase in in-
tracellular cAMP, calcium and insulin-like growth factors (Naot and
Cornish, 2008; Togari et al., 1997; Uzan et al., 2004; Villa et al., 2006).
In contrast to CGRP, themolecular mechanisms that regulate STC1
action remain largely unknown. A speciﬁc STC1 receptor has not
yet been identiﬁed, which makes the functional characterization of
the protein more diﬃcult. Based on the fact that calcitonin family
peptides and STC1 act on bone metabolism, we hypothesize that
their signaling pathways may interact with each other. Recently in
the zebraﬁsh embryo model, it was demonstrated that overpro-
duction of CT peptide increased by 3-fold the expression of STC1
suggesting a feedback mechanism between the two hormones
(Lafont et al., 2011). Thus, the present study was designed to better
elucidate the role of STC1 in human bone formation/remodeling by
investigating the potential role of STC1 on CGRP signaling during
the differentiation of osteoblast, and to determine whether STC1
modulates CTR and the CGRP functional receptor. The abundance
of CALCRL/RAMP1 transcript, themodulation of the receptor complex
in cell plasma membrane and the inﬂuence of STC1 on CGRP in-
tracellular signaling were studied using human pre-osteoblasts
adipose derived stem cells and receptor transfected human em-
bryonic kidney cell lines.
2. Materials and methods
2.1. Cell lines and culture maintenance
Commercially available PoieticsTM human adipose derived stem
cells (hADSC) isolated from lipoaspirates were purchased from Lonza
(Lonza Group, Switzerland). Cells were maintained as adherent cul-
tures in complete Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Sigma, Spain) supplemented with 10% fetal bovine serum (FBS), 0.1%
penicillin:streptomycin antibiotic mix (10.000 U:10 mg/ml, Sigma,
Spain) and 250 μg/ml sterile ﬁltered 1:100 amphotericin B solu-
tion (Sigma, Spain) at 37 °C/5% CO2. Media were changed every 3
days, and the cells were split when they reached 80–90% conﬂu-
ence. Cells were used at early passage (4–8 passages) for all
experiments. Human Embryonic Kidney (HEK) 293 cells (ECACC col-
lection, UK) were maintained at 37 °C/5% CO2 in complete DMEM
supplemented with FBS as previously described and divided every
3–4 days 80–90% conﬂuence was reached.
2.2. hADSCs osteoblastic differentiation
hADSCwere differentiated to pre-osteoblast for 7, 14, and 21 days,
using osteoblastogenic differentiation medium consisting of DMEM
supplementedwith 10% FBS, 50 μM ascorbate-2-phosphate, 100mM
beta-glycerophosphate, and 0.1 μMdexamethasone, according to pre-
viously published techniques (Zuk et al., 2002). To conﬁrm the
osteogenic phenotype, differentiated cells were ﬁxed in 4% PFA,
rinsed with PBS and stained with Alizarin Red S for 5 minutes and
imaged with light microscopy.
2.3. ATP assay
ATP concentration is used as a marker for cell viability because
its concentration rapidly declines when cells undergo necrosis or
apoptosis. hADSCs were differentiated to pre-osteoblast cells using
the osteoblastogenic cocktail supplemented with increased doses
of human STC1 (5.0, 50 and 2000 pM; hSTC1, Biovendor, Czech Re-
public) (Basini et al., 2009) to eliminate the hypothesis that STC1
could induce cell death during osteoblastogenesis. The effects of
hSTC1 on the intracellular ATP pool were measured on day 7 after
the beginning of the osteoblastic induction. After the experimen-
tal period, cells were collected and immediately frozen in liquid
nitrogen prior to homogenization in lysis buffer (TCA 6%, NaF 20mM,
Gelatin 0.4 g.l−1). ATP was determined using the bioluminescent
luciferin kit (Invitrogen, USA) according to the manufacturer’s
protocol. Results obtained were expressed as intracellular ATP
concentration (pM).
2.4. Isolation and cloning of CALCRL and ramp1
The human CALCRL and ramp1mRNAswere isolated from hADSCs
differentiated to osteoblast cells. The human CALCRL full-length tran-
script was ampliﬁed from cDNA (see discussion later) using the
primers forward 5′ atggagaaaaagtgtaccctgaat and reverse 5′
tcaattatataaattttctggttttaag (annealing temperature 54 °C, 35 cycles)
and ramp1 with primers forward 5′ atggcccgggccctgtgccgcct and
reverse 5′ ctacacaatgccctcagtgcgcttg (annealing temperature 64 °C,
40 cycles). All PCR reactions were performed using the Taq DNA
Polimerase High Fidelity (Invitrogen, USA) for a ﬁnal reaction of 50 μl
according to the manufacturer’s protocol. PCR products obtained
were run on 1% agarose/1× TBE gels and products of the correct size
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were cloned in pGEM T-easy vector (Promega) and sequenced to
conﬁrm identity. The human CALCRL and ramp1 transcripts were am-
pliﬁed from the cloning vector using the iProof DNA polymerase
(BioRad, Portugal) according to the previously described condi-
tions and the PCR products obtained were puriﬁed and sub-
cloned into the expression pcDNA3.1 vector (Directional TOPO
Expression Kit, Invitrogen, USA). The ligation product was used to
transform DH5-alpha E. coli bacteria. Bacteria containing the correct
construct were selected and recombinant plasmids were ex-
tracted using the GeneJet TM plasmid Miniprep kit (Fermentas,
Portugal). All puriﬁed plasmids were used to transfect human
HEK293 cells for intracellular signaling assays.
The human calcitonin receptor (CTR; CALCR gene) clone in pcDNA
3.1 expression vector was purchased from Missouri S&T cDNA
resource Center, USA (catalog number CALCR 00000) and used in
the transfection assays (as described earlier) as a model of com-
parison on cAMP assays (see discussion later).
2.5. RNA extraction, cDNA synthesis and quantitative expression
To analyze the effect of hSTC1 on CALCRL and ramp1 mRNA ex-
pression during human osteoblastogenesis, hADSCs cells were
differentiated to osteoblasts for up to 21days using the osteoblastogenic
cocktail supplemented with 2 nM hSTC1. Cells were collected at
days 7, 14 and 21. Brieﬂy, semi-conﬂuent cultures of undifferentiated
hADSCs and pre-osteoblast cells werewashed three timeswith 1× PBS
and harvested by centrifugation. Total RNA was extracted with Trizol
(Invitrogen, USA) according to the manufacturer’s instructions. RNA
quantity was assessed by absorbance in the BioPhotometer plus
(Eppendorf, USA) and quality was checked by electrophoresis on 1.5%
agarose gels.
cDNA was synthesized with 2 μg of total RNA in a reaction
mixture containing 5 mM of DTT, 0.5 mM dNTPs mixture (Ludwig
Biotech, Brazil), 1.0 μg of random hexamers (pd(N)6), 10 U rRNAsin
RNase inhibitor (Promega, USA), 50 U MMuLV reverse transcriptase
(Thermo Scientiﬁc, USA) for a 20 μl ﬁnal reaction volume comple-
mented with sterile distilled water. The cDNA synthesis reaction was
performed as follows: 10min at 25 °C followed by 120min at 37 °C
and ﬁnally 10 min at 65 °C to inactivate enzyme activity.
Semi quantitative real-time reverse-transcriptase PCR (RT-
PCR) analyses were run using speciﬁc primer pairs for CALCRL and
ramp1. Primer sequences for RT-PCR were designed using the IDT
Design Software (Integrated DNA Technologies Inc., USA) to distin-
guish exons. Primer sequences were assessed for speciﬁcity using
non-redundant basic local alignment search tools (www.ncbi
.nlm.nih.gov/BLAST) (Altschul et al., 1990) and target-speciﬁc se-
quence alignment programs (Espinosa et al., 2013). Tbp was used
as reference gene and the results presented relative to Tbp expres-
sion. Primer pairs were: CALCRL forward 5′ gatttccactgattcctgcttg
(exon 11); reverse 5′ ggcaccaagataagagtagctc (exon 13) (amplicon
size: 218pb; NM_005795.4); ramp1 forward 5′ atcacctcttcatgaccactg
(exon 2); reverse 5′ cctgtccacctctgcatt (exon 3) (amplicon size: 218pb;
NM_005855.2). RT-PCR reactions were performed with 0.1 μM of
each speciﬁc primer, 0.5 ng/μl cDNA and Platinum® SYBR® Green
qPCR SuperMix-UDGwith ROX (Invitrogen, USA). The thermal cycling
conditions used were: 2 min at 50 °C, 2 min at 95 °C, followed by
40 cycles of 95 °C for 15 s, 60 °C for 30 s. Under these conditions,
RT-PCR produced a single product at the melting temperature for
each analyzed gene. Control reactions (cDNA synthesis reaction
without reverse transcriptase) were performed to verify genomic
DNA contamination. The mean Ct values from triplicate measure-
ments were used to calculate expression of the target gene, with
normalization to internal control (Tbp) using the 2–ΔΔCt formula
(Schmittgen and Livak, 2008). All gene expression results are based
on 3 independent experiments.
2.6. Laser-scanning confocal microscopy
To quantify the CALCRL and RAMP1 protein expression on plasma
membrane of hADSCs and 7-days differentiated pre-osteoblasts and
to verify the effects of hSTC1 peptide on the distribution pattern of
the CGRP heterodimeric receptor complex, an immunocytochem-
istry assay was performed and confocal microscopy analysis was
carried out. Brieﬂy, hADSCwere cultured at the aforementioned con-
ditions on 4-chamber glass bottom dishes and were differentiated
to pre-osteoblasts during 7 days without hSTC1. Sequentially, hADSCs
and pre-osteoblasts were exposed to 2.0 nM of hSTC1 or 2.0 nM of
human CGRP for 30min at 4 °C (hCGRP, cat. number C 0167; Sigma-
Aldrich, São Paulo, Brazil). A number of studies that describe the
biological effects of STC1 in vitro used STC1 at 0.1–15 nM, however,
the STC1 effects at doses ranging from 1 nM to 10 nM were found
to be very similar (Sazonova et al., 2008; Zlot et al., 2003) . Thus,
the concentrations of STC1 and hCGRP used in the experiments
(2 nM) were chosen based on studies of Granholm et al. (2011), Zlot
et al. (2003), Yoshiko et al. (2003) andWang et al. (2010). The hCGRP
peptide was used as a positive control since it is the native ligand
of the heterodimeric CALCRL/RAMP1 receptor complex (Bailey et al.,
2012; Hay et al., 2005; McLatchie et al., 1998; Naot and Cornish,
2008).Unexposed cells were used as control. After hSTC1 or hCGRP
exposure, cells were washed and incubated with rabbit polyclonal
antibody against human CALCRL (clone H-42, cat. no. SC30028) and
goat polyclonal antibody against human RAMP1 (clone N-20, cat.
no. SC8050) (both from Santa Cruz Biotechnology, USA) diluted in
a PBS/blockage solution with 5% of FBS plus 1% of bovine serum
albumin (BSA) at 4 °C for 1 h to reduce background staining. Further,
cells werewashed, ﬁxedwith 4% paraformaldehyde in PBS for 20min
before incubation at 4 °C with anti-rabbit antibody conjugated with
the green ﬂuorescent Alexa Fluor® 488 and anti-goat antibody con-
jugated with red ﬂuorescent Alexa Fluor® 555 (both from Life
Technologies, USA), which were used to label the primary antibod-
ies for CALCRL and RAMP1, respectively (Vilcaes et al., 2011). Ten
single confocal sections of 0.7 μm were taken parallel to the cov-
erslip (xy sections) on the Olympus FV1000 laser-scanning confocal
microscopy equipped with an ×60 (numeric aperture 1.35) oil-
immersion objective (Olympus, U plan-super-apochromat,
UPLSAPO60XO). The CALCRL ﬂuorescence was acquired after exci-
tation by a 488 nm laser beam and the emission scan collected at
520 nm. The RAMP1 ﬂuorescence was acquired after laser excita-
tion at 555 nm and emission collected at 647 nm. Imaging analysis
is based on 3 independent experiments. Images of three ﬁelds of
each sample were acquired with Olympus FluoView FV1000
software. Imaging pre-processing (iterative deconvolution) and
ﬂuorescence intensitymeasurementwere performed using the public
domain Java Image processing software imageJ (http://rsb.info
.nih.gov/ij/). Fluorescence emission for CALCRL and RAMP1 was
measured by establishing multiple regions of interest (ROI) that
surrounded cell boundary thus intending to reduce background in-
terference in all acquired images. To conﬁrm the viewed proximity
between CALCRL and RAMP1, co-localization analysis was per-
formed in all images using the JACoP plugin as previously described
(Bolte and Cordelieres, 2006; Dunn et al., 2011; Zinchuk et al., 2007).
Pearson’s coeﬃcients were calculated considering Costes’s auto-
matic threshold that seeks to reduce nonspeciﬁc correlations (Costes
et al., 2004).
2.7. Mammalian cell transfections with the CGRP heterodimeric
receptor complex CALCRL/RAMP1
On the day prior to transfection, 2–3 × 105 cells were seeded in
6-well plates (Sarstedt, Portugal) and cells were transiently trans-
fected with Fugene 6 transfection reagent (1:6 DNA:Fugene,
Roche; USA) according to the manufacturer’s protocol. Brieﬂy, the
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DNA transfection complex was incubated for 40 min at room tem-
perature before adding to the cells. Cells with the transfection
complex were incubated with 500 μl of DMEMmedium for 6 h prior
to addition of complete medium to a ﬁnal volume of 2 ml per well.
Human CALCRLwas transfected in a human RAMP1 stable HEK293
cell line. The stable RAMP1 cell line was generated using the linear-
ized expression construct and 72h after incubation, cellswere selected
by supplementing the complete medium with 800 μg/ml of the an-
tibiotic geneticin (G418 sulphate, Gibco® Life Technologies, USA). The
human RAMP1-pcDNA3 expression plasmid was constructed using
a methodology similar to that previously described for the recep-
tors. Prior to transfection, 5 μg of the plasmid was linearized using
the NotI enzyme (Thermo Scientiﬁc, Fermentas, Portugal) and puri-
ﬁed using the standard phenol:chloroformmethod. Cell recoverywas
monitored daily by constant changes of medium until no cell death
was observed. RT-PCR using ramp1 speciﬁc primers conﬁrmed gene
integration and transcript expression. The eﬃciencies of the cell trans-
fections were obtained by performing a simultaneous transfection
using the pCMV-EGFP vector (Clontech, USA). The human CTR was
transiently transfected on wild HEK293 cells using the same proto-
col described earlier and used for comparisons with CALCRL. The
receptor pharmacological responses to the hSTC1, hGCRP or human
CT (human calcitonin cat no. T3535, Sigma, Spain) peptides to acti-
vate the human CALCRL-RAMP1 and CTR on cAMP-signaling pathway
were assayed 72 h post transfections.
2.8. cAMP-signaling pathway
The capacity of the human STC1, CGRP and CT peptides to ac-
tivate transfected CALCRL/RAMP1 and CTR HEK293 transfected cells
and human 7 days pre-osteoblast cultures was measured by quan-
tiﬁcation of intracellular cAMP using the cAMP dynamic 2 kit (Cisbio,
France) following themanufacturer’s protocol. Approximately 15,000
of transfected cells/well were assayed and peptide incubations were
performed in white 384 well small Volume™ HiBase Polystyrene
microplates (Greiner, Germany). The osteoblast cell line was also
accessed for cAMP production in the presence of the hSTC1 and
hCGRP peptides using cells that derived from a 100% conﬂuent
culture on a T25 bottle due to their slow growth and diﬃculty to
dislodge from the plastic.
Cell assays were performed for a ﬁnal reaction volume of 20 μl.
Prior to the assay, cells were re-suspended in 1× PBS with 1 mM
of 3-isobutyl-1-methylxantine (IBMX, Sigma, Spain) and incu-
bated for 5 min at 37 °C. Peptides diluted to a ﬁnal concentration
of 1–0.1 μM in 1× PBS/1 mM IBMX were added to the cells and in-
cubated for 30 min at 37 °C in the CO2 incubator. Non-transfected
HEK293 cells were used as negative control and were stimulate with
the highest STC1, CGRP and CT peptide concentration (1 μM).
Forskolin (5 μM, Sigma, Spain) was used as positive control to assess
cellular responsiveness of the cAMP pathway. For the calcula-
tions, two additional assay controls were also performed according
to themanufacturer’s instructions: (a) a negative background control
without cAMP-d2 and (b) a non-stimulated control (no peptide
added). Plates were read using a Biotek Synergy 4 plate reader
(Biotek, USA) and results of cAMP stimulation were normalized ac-
cording to the manufacturer’s recommendations for data analysis.
To test the peptides capacity to stimulate cell cAMP production,
assays were initially performed using 1 μM and 0.1 μM of the hSTC1
and hCGRP on CGRP receptor complex and 1 μM and 0.1 μM of the
hSTC1 and 0.1 μM of CT on the CTR transfected cells. The doses se-
lected for the assays were based on the cell responsiveness to peptide
stimulation and previous studies (Granholm et al., 2011;Wang et al.,
2011).
To assess the effect of hSTC1 on the inhibition of cAMP produc-
tion, native HEK293 cells were initially stimulated with 5 μM of
forskolin for 30min to achievemaximum cAMP production and then
incubated for an additional 30 min with 0.1 μM or 1 μM of hSTC1.
Maximum cAMP production of the receptor transfected cells was
also stimulated by initially incubating CALCRL/RAMP1 and CTR
HEK293 transfected cells for 30 min with 0.1 μM of the hCGRP and
CT peptides, respectively followed by 30 min with 0.1 μM or 1 μM
of hSTC1. To access if hSTC1 utilizes the CALCRL/RAMP1 complex
and inhibits CGRP binding, transfected cells were also initially stimu-
lated with 0.1 μM of hSTC1 for 30 min followed by 0.1 μM or 1 μM
of hCGRP peptide for 30 min. Similar assays for the CTR were also
performed using 0.1 μM or 1 μM of hCT peptide for 30 min. The
amount of cAMP produced by non-transfected receptor cells was
subtracted and assay data were normalized as percentage of cAMP
accumulation. The effect of the empty receptor vector in cell sig-
naling was also tested and values were equivalent to the peptide
assays using non-transfected cells.
2.9. Intracellular calcium release
The effect of hSTC1 to stimulate intracellular Ca2+ (iCa2+) release
(RFU) was measured using the Ca2+ sensitive ﬂuorescent dye Fluo-4
NW (Molecular Probes, Invitrogen, USA) according to the manufa-
cturer’s instructions on hADSCs, 7 days pre-osteoblast cultures,
receptor transfected cell lines CALCRL/RAMP1 and CTR. Prior to the
assay, plates (96 well black/plates, μClear bottom, Greiner, Germany)
were coated with sterile poly-L-lysine (0.1 mg/ml, Sigma, Spain) to
avoid cell release. Approximately 50,000 cells re-suspended in 100 μl
of complete DMEMmediumwere plated per well and were allowed
to attach overnight at 37 °C in a humid 5% CO2 incubator. Prior to
the assay, growthmediumwas removed and cells werewashed twice
with 1× PBS and incubated for 30min at 37 °C with 100 μl of Fluo-4
NW dye followed by an additional 30 min incubation period at RT.
The background RFU of each well was measured prior to addition
of the peptide and receptor response was carried out using 0.1 μM
of hSTC1 peptide diluted in assay buffer. Calciummobilization pro-
voked by the presence of the peptide was measured every 10 s over
a total period of 2 min on the plate reader. Positive control assays
were performed with 100 nM Carbachol (Sigma-Aldrich, Spain) and
negative control assays were performed using non-transfected
HEK293 cells stimulated with 0.1 μM of hSTC1. Background ﬂuo-
rescence wasmeasured in each assay by adding 10 μl of assay buffer.
Maximal RFU values were used for calculations, which entailed sub-
traction of background values and data normalization before plotting
RFU values against peptide concentration.
2.10. Statistical analysis
Statistical analysis was performed using SigmaStat (v. 3.50, Systat
Software, Inc, San Jose, CA, USA). Gene expression and cAMP data
were evaluated using one-way or two-way ANOVA when appro-
priated, followed by the Bonferroni multiple comparison procedures.
Before applying the ANOVA test, data were checked for normality
(Kolmogorof–Smirnov test) and homogeneity (Levene test). In the
absence of homogeneity, data were log-transformed prior to the
ANOVA test. Protein expression was analyzed by Student’s t-test (see
Supplementary material). Data are presented as the mean ± stan-
dard error of the mean (SEM) and the level of statistical signiﬁcance
was P < 0.05. Each experiment was repeated three to six times.
3. Results
3.1. Effect of hSTC1 on osteoblasts ATP levels
Increased concentrations of hSTC1 (5.0, 50 and 2000 pM) during
osteoblastogenesis did not modify the intracellular levels of ATP, in-
dicating that hSTC1 peptide incubations did not affect human
osteoblast cell viability (see Supplementary material, Fig. S1).
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3.2. Effect of hSTC1 on CGRP signaling
3.2.1. Effect on CGRP receptor complex expression
CALCRL gene expression was low in undifferentiated hADSC
and did not change over time. However, in differentiating cells
and hSTC1-treated cells, the expression of CALCRL was signiﬁ-
cantly elevated at 7 days compared to undifferentiated hADSC
and by 21 days levels were similar between the three groups of
cells (see Supplementary material, Fig. S2, A). Ramp1 gene expres-
sion was generally low and only elevated in untreated differentiated
cells at 7 and 14 days (see Supplementary material, Fig. S2, B).
Ramp1 transcript expression was not affected by STC1 peptide
treatment.
CALCRL and RAMP1 proteins were present at the plasma mem-
brane cell surface of hADSCs and 7-day pre-osteoblast cells, as
revealed by immunoﬂuorescence (Figs. 1 and 2 and Fig. S3). CALCRL
expression was highest at day 7 compared to non-differentiated
hADSC, in agreement to the mRNA expression results. There was
no statistical difference in RAMP1 protein expression during the same
time period (see Supplementary material, Fig. S3).
3.2.2. Effect of hSTC1 or hCGRP on the CGRP heterodimeric receptor
complex CALCRL/RAMP1
The expression of the CGRP heterodimeric receptor complex on
the cell membrane surface was evaluated in hADSCs (Fig. 1) and in
7-day pre-osteoblast cells (Fig. 2) by confocal microscopy in the
absence and presence of hSTC1 and hCGRP peptides. The overall co-
localization between the CALCRL/RAMP1monomers was conﬁrmed
by calculating Pearson’s coeﬃcient and can be observed in orange
in the merged images that were obtained by superimposition of the
green- and red-labeled ﬂuorescent images (Figs 1 and 2). Incuba-
tion with 2 nM of hSTC1 or hCGRP for 30 min modiﬁed the spatial
localization of CALCRL and RAMP1, eliciting a cluster of the recep-
tor complex in speciﬁc areas at the surface of both types of cells,
indicating a similar effect of both hSTC1 and hCGRP peptides.
3.2.3. Effect of hSTC1 or hCGRP on cAMP and iCa2+ cell signaling
Incubation of 7-day differentiated human osteoblast cells with
0.1 μM hCGRP, but not hSTC1, promoted cAMP accumulation. This
indicates that CGRP receptor complex is expressed and functional
at the osteoblast cell plasma membrane and suggests that the effect
Fig. 1. Spatial distribution of CGRP heterodimeric receptor in the presence of hCGRP and hSTC1 on the cell surface of human adipose derived stem cells (hADSCs) demon-
strated by immunocytochemistry. Green ﬂuorescence indicates the presence of CALCRL receptors; red ﬂuorescence indicates RAMP1 accessory protein. Overlapping of CALCRL
and RAMP1 images (MERGE) revealed that both proteins are in the same cellular microcompartment. hADSCs were grown on 4-chamber glass bottom dishes, then exposed
to hCGRP (2 nM) or hSTC1 (2 nM) diluted in DMEM for 30 min. Unexposed cells were used as negative control (hASDC). Cells were immunostained for CALCRL and RAMP1
as indicated under Section 2. Both proteins seem to be close to each other at the cell surface of unexposed hADSCs. Incubation with STC1 or CGRP modiﬁed the spatial
localization of CALCRL and RAMP1, eliciting a concentration of the receptor complex in speciﬁc areas at the cell surface (white arrows head). Pearson’s coeﬃcients of cor-
relation for all the overlapping CALCRL and RAMP1 images were: 0.65 ± 0.02 for control; 0.64 ± 0.01 for hCGRP and 0.55 ± 0.03 for hSTC1. The ﬂuorescence images are representative
of three independent experiments. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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CGRP in osteoblasts involves the cAMP pathway (Fig. 3A) but the
signaling of STC1 remains unknown.
In vitro studies with HEK293 cells were used to clarify the po-
tential interference of hSTC1 in hCGRP signaling. The hSTC1 failed
to increase the cAMP levels in native HEK293 cells (Fig. 3B). However,
in HEK293 cells ﬁrst stimulatedwith forskolin to induce cell maximal
cAMP accumulation, hSTC1 decreased cAMP levels in a dose-
dependent manner (Fig. 3C). In contrast incubation with CGRP failed
to induce cAMP accumulation (not shown), conﬁrming that HEK293
do not express the CGRP functional complex (Atwood et al., 2011).
These results indicate that a putative STC1 receptor is naturally
expressed in HEK293 cells, suggesting that the observed hSTC1 sig-
naling is not via CGRP functional receptor complex (Fig. 3C).
hCGRP was also able to activate cAMP accumulation in HEK293
CALCRL/RAMP1 transfected cells and an increase of cAMP levels was
obtained when 1.0 μM of hCGRP was used in comparison to 0.1 μM
(Fig. 4A). In contrast, no signal was obtained when hSTC1 was in-
cubated with HEK293 CALCRL/RAMP1 transfected cell lines. In vitro
cell assays using HEK293 expressing the CTR were also performed
to compare the effect of STC1 in CGRP functional complex. The hCT
peptide also stimulated cAMP in CTR transfected cells (Fig. 4B) but
not in non-transfected HEK293 (not shown) conforming that HEK293
also do not express the CT receptor (Atwood et al., 2011). Similar
to CALCRL/RAMP1, incubations using hSTC1 in HEK293 CTR trans-
fected cells primedwith hCT also induced a decrease of the cell cAMP
levels (Fig. 4B).
CALCRL/RAMP1 and CTR transfected cells were also stimulated
using different combinations of hCGRP/hCT and hSTC1 peptides
to investigate the existence of potential peptide interactions by
accessing the receptor response on cAMP production. In cells pre-
incubated with 0.1 μM of hCGRP, addition of 0.1 μM and 1.0 μM of
hSTC1 does not seem to modify cAMP accumulation. However, a
dose-dependent decrease in cAMP accumulation was observed in
hCT stimulated cells when hSTC1 was added (Fig. 4A and B). Sim-
ilarly when receptor transfected cells were pre-incubatedwith hSTC1
(0.1 μM), addition of hCGRP and hCT also show different responses
on the cell levels of cAMP. The presence of 1.0 μM of hCGRP sig-
niﬁcantly increased the cell cAMP (p < 0.05) to levels higher than
1.0 μM hCGRP alone (Fig. 4A) but a signiﬁcant reduction (p < 0.05)
of cAMP was observed in cells ﬁrst primed with hSTC1 and subse-
quently with hCT when compared to hCT at 0.1 μM and 1.0 μM
(Fig. 4B).
We also investigated the receptor response to intracellular calcium
mobilization in the presence of hSTC1. The 7-day differentiated
Fig. 2. Spatial distribution of CGRP heterodimeric receptor in the presence of hCGRP and hSTC1 on the cell surface of pre-osteoblasts demonstrated by immunocytochem-
istry. Green ﬂuorescence indicates the presence of CALCRL receptors; red ﬂuorescence indicates RAMP1 accessory protein. Overlapping of CALCRL and RAMP1 images (MERGE)
revealed that both proteins are in the same cellular microcompartment. hADSCs were differentiated to 7-days pre-osteoblasts on 4-chamber glass bottom dishes, then exposed
to hCGRP (2 nM) or hSTC1 (2 nM) diluted in osteoblastogenic cocktail for 30 min. Unexposed 7-days pre-osteoblasts were used as negative control. Cells were immunostained
for CALCRL and RAMP1 as indicated under Section 2. Both proteins seem to be close to each other at the cell surface of unexposed 7-days pre-osteoblasts. Incubation with
hSTC1 or hCGRP modiﬁed the spatial localization of CALCRL and RAMP1, eliciting a concentration of the receptor complex in speciﬁc areas at the cell surface (white arrows
head). Pearson’s coeﬃcients of correlation were 0.64 ± 0.02 for control pre-osteoblasts, 0.64 ± 0.02 for the hCGRP peptide incubations and 0.71 ± 0.01 for hSTC1 peptide in-
cubations, suggesting that the presence of hSTC1 favored the assembly of the CALCRL and RAMP1 complex. The ﬂuorescence images are representative of three independent
experiments. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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human osteoblasts, native and transfected HEK293 cells ex-
pressing the human CGRP heterodimeric complex receptor or
CTR receptor incubated with 0.1 μM of hSTC1 failed to mobilize
calcium.
4. Discussion
The present study demonstrates that during the early period of
osteoblastic differentiation, the hADSCs pre-osteoblast derived cells
express the highest levels of the CALCRL/RAMP1 heterodimer
complex. Furthermore, it shows that hSTC1 is able to elicit cluster-
ing of the CALCRL/RAMP1 heterodimer complex receptor in speciﬁc
areas at the cell membrane. STC1 signal via inhibition of cAMP levels
and the presence of the STC1 do not seem to affect cAMP levels
induced by hCGRP, but inhibit the action of hCT via CTR.
Several lines of evidence indicate that STC1 (Yoshiko et al., 2002,
2003) and CGRP (Schinke et al., 2004; Wang et al., 2010) are asso-
ciated with the same processes in osteoblast cells. In the absence
of a cognate STC1 receptor we focus on the potential interaction
between STC1 and CGRP signaling during osteoblastic differentiation.
The CGRP receptor is a dimeric complex of CALCRL and RAMP1,
needing the presence of both for peptide activation (Aiyar et al., 1996;
McLatchie et al., 1998; Roh et al., 2004; Smillie and Brain, 2011).
The CALCRL/RAMP1 complex was detected in several osteoblastic
lineages, including mouse MC3T3-E1, MG63 osteoblastic cell lines,
rat primary calvarial osteoblasts and human primary osteoblast cell
cultures (Schinke et al., 2004; Togari et al., 1997; Uzan et al., 2004;
Villa et al., 2006). The effects of CGRP in osteoprogenitor cells are
predominant in the earlier stages of the differentiation process (in
the ﬁrst 2 weeks) prior the mineralization onset (Naot and Cornish,
2008; Wang et al., 2010).
When osteoblast cells are stimulated by CGRP, the CALCRL/
RAMP1 heterodimeric complex increases adenylate cyclase (AC)
activity and, consequently, intracellular cAMP levels (Chang and Hsu,
2013; Kawase et al., 2003; Villa et al., 2006). In contrast, in the
present study, hSTC1 alone had no effect on CALCRL and Ramp1 gene
expression and iCa2+ release in any of the cell types studied (un-
differentiated, differentiating and HEK293 cells). Moreover, it
inhibited cAMP buildup in HEK293 cells primed by forskolin but does
not seem to modify cAMP levels on CALCRL/RAMP-transfected cells
when hCGRP is present. This indicates that HEK293 cells express a
functional STC1 receptor and that the presence of STC1 does not
seem to modify CGRP functional complex response to CGRP. In con-
trast, STC1 inhibits CT induced intracellular cAMP formation in CTR
over-expressing HEK293 cells. In fact, the results obtained in our
study provide evidence that hSTC1 seems to interfere with hCT
potency for cAMP production. Moreover we were able to demon-
strate that the presence of STC1 inhibits CT peptide function by
decreasing the peptide potency to produce cAMP in cells in both
combinatory in vitro peptide assays performed. The distinct effect
of hSTC1 on cAMP levels elicited by hCGRP and hCT peptides may
be related with the different capacities that both peptides had on
cAMP production in vitro and that hCT was more potent than hCGRP
in the HEK293 cell assay. Cross regulation of CT and STC has pre-
viously been suggested and an increase of CT peptide production
in zebraﬁsh eggs was shown to stimulate the increase expression
of STC1 transcript resulting in a decrease of total calcium (Lafont
et al., 2011). The ﬁsh data may indicate that the action of CT and
STC1 may be coordinated in tetrapods and that STC1 may inhibit
the role of CT in vivo, as suggested by our cAMP in vitro assays.
Since intracellular cAMP accumulation and calcium mobiliza-
tion were not detected in response to STC1, it is unlikely that STC1
signaling occurs through a Gαs or Gαq coupled-GPCR in these cell
lines. Despite previous suggestions of STC1 activation and signal-
ing via cAMP–PKA pathway in ﬁsh tubular proximal cells (Lu et al.,
1994), or improved calciumwaves evoked by extracellular ATP (Block
et al., 2010). Our results indicate that STC1 inhibits cAMP accumu-
lation possibly through a Gαi coupled-receptor signaling or through
unrelated GPCR receptor(s). The inhibition of cAMP synthesis by Gαi
results in decreased activity of cAMP-dependent protein kinase
(Skalhegg and Tasken, 2000). It appears that STC1 may bind to a Gαi
Fig. 3. Intracellular cAMP induced by hCGRP and hSTC1 peptides. (A) cAMP accu-
mulation in pre-osteoblast cells differentiated from human adipose derived stem cells
(hADSCs) after incubation with hCGRP (0.1 μM) and hSTC1 (0.1 μM). cAMP was mea-
sured after treatment with forskolin (FK, 5 μM), CGRP or STC1 for 30 min. (B) cAMP
accumulation in non-transfected HEK293 cell lines stimulated by FK (5 μM) and hSTC1.
(C) FK treated cells were subsequently incubated with STC1 (0.01 μM, 0.1 μM and
1.0 μM) for 30min. Statistical differences were estimated using one-way ANOVA and
different letters above bars indicate statistical signiﬁcance of the 5% level.
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coupled-receptor (Gαi coupled-GPCR), which in turn blocks AC ac-
tivity inside the cell with subsequent decrease in intracellular cAMP
formation. This hypothesis is also supported by two other fea-
tures: ﬁrstly, ERK1/2 (Nguyen et al., 2009) and cAMP/CREB pathways
(Lu et al., 1994; Yeung et al., 2012; Yoshiko et al., 1996) are in-
volved in STC1 intracellular signaling; secondly, Gαi coupled-
GPCR stimulation can activate the ERK1/2 pathway through a
downstream phosphorylation cascade, which activates RAS, RAF and
Fig. 4. cAMP accumulation in CALCRL/RAMP1 and CTR expressing HEK293 cell lines stimulated by hSTC1, hCGRP and hCT. (A) CALCRL/RAMP1 transfected cells were treated
with hSTC1 (0.1 μM and 1.0 μM) or hCGRP (0.1 μM and 1.0 μM) for 30 min before cAMP measure. To examine if hSTC interferes with hCGRP cAMP production, cells were
pre-treated with hCGRP (0.1 μM) or with hSTC1 (0.1 μM) for 30 min and subsequently with hSTC1 (0.1 μM and 1.0 μM) or hCGRP (0.1 μM and 1.0 μM), respectively for 30 min.
(B) CTR transfected cells were treated with hSTC1 (0.1 μM and 1.0 μM) or hCT (0.1 μM) for 30 min before cAMP measure. To examine if hSTC interferes with hCT cAMP pro-
duction, cells were pre-treated with hCT (0.1 μM) or with hSTC1 (0.1 μM) for 30min and subsequently with hSTC1 (0.1 μM and 1.0 μM) or hCT (0.1 μM and 1.0 μM), respectively
for 30 min. Bars (mean ± SEM) indicate the percentage of cAMP levels in relation to maximal FK stimulation of at least three independent experiments performed in trip-
licate. Statistical differences were estimated using two-way ANOVA and different letters above bars indicate statistical signiﬁcance of the 5% level.
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MEK, culminating in migration of the transcription factors ELK1 and/
or CREB to the nucleus (Avlani et al., 2013; Goldsmith and
Dhanasekaran, 2007).
Similar inhibitory results on cAMP have been obtained using rat
osteosarcoma cell lines incubated with human parathyroid hormone
(PTH) plus a synthetic teleost N-terminal STC1 truncated peptide
(Yoshiko et al., 1996). The ﬁsh N-terminal STC1 had a suppressing
effect on cAMP accumulation evoked by PTH. Furthermore, in assays
in which granulosa cells were incubated with 10 ng/ml of FSH, or
hCG, plus 10 nM of STC1, a signiﬁcant reduction in cAMP was also
detected (Luo et al., 2004). Thus, it seems that STC1 activates similar
signaling pathways independently of the cell line used, via inhibi-
tion of cAMP accumulation. Moreover, it is unlikely that STC1 inhibits
intracellular cAMP levels by stimulating phosphodiesterase (PDE)
activity, given that PDE activity was blocked by IBMX before the be-
ginning of the cAMP assays. The measurements of intracellular ATP
during osteoblastogenesis indicated that ATP levels are not affect-
ed by long-term treatment with hSTC1. Therefore, it is also unlikely
that hSTC1 may reduce intracellular ATP, which must be available
as a substrate for cAMP formation. Although HEK293 cell viability
when incubated with STC1 was not measured, it is unlikely that the
peptide affects cell function since vertebrate kidney cell lines nor-
mally express high levels of STC1 (Sazonova et al., 2008) and
commercially available recombinant STC1 is produced in HEK cells.
Surprisingly, when CALCRL/RAMP1 transfected cells were pre-
incubated with hSTC1 and subsequently with CGRP, the hCGRP
stimulation of cAMP accumulation was more eﬃcient than hCGRP
alone. The increase of cAMP production in the presence of CGRP is
intriguing and further studies are required. However, it is most likely
to be an example of a paradoxical enhancement or sensitization of
AC activity that results in increased cAMP accumulation when the
action of the inhibitory receptor is ended (Watts and Neve, 2005).
This has been interpreted as an adaptive response to the chronic
inhibition. Moreover, confocal immunocytochemistry analysis also
suggests that STC1 may interfere in the CGRP receptor localization
in differentiated 7-day pre-osteoblasts by an unknown interaction
and/or translocation mechanism at the plasma membrane level.
However, how this modiﬁes receptor signaling response remains
to be established.
Taken together, the present results indicate an interaction of STC1
with the CGRP heterodimeric receptor complex CALCRL/RAMP1with
a possible speciﬁc cross-talk between STC1 and CGRP signaling during
osteoblastogenesis. Further evaluation is required in order to estab-
lish the possible mechanism for this interaction. STC1 was also able
to inhibit the CT signaling on CTR transfected cells and since CTR is
also expressed on osteoblasts (Monier-Faugere et al., 1996; Villa et al.,
2003) this results point out a possible important role of STC1 on the
inhibition of the CT signaling during the osteoblastogenesis process.
Although binding assays have not been performed, evidence in-
dicates that STC1 does not seem to share the same receptors than
CGRP and CT; nonetheless the presence of STC1 seems to interfere
with peptide signaling. Furthermore, future studies are necessary
to clarify our new data about STC1 intracellular cAMP inhibition,
such as the use of pertussis toxin that inhibit Gi proteins, co-
precipitation assays as well as activation and phosphorylation of
intracellular signaling molecules including MAP kinase and ERK.
5. Conclusions
To the best of our knowledge, this is the ﬁrst investigation of a
possible link between STC1 and CGRP and CT signaling during
osteoblastogenesis. Our study indicates a cross-talk between CGRP
and STC1 at the earlier stages of the osteoblast differentiation process.
In addition to the previously reported direct effects on osteogen-
esis, our study shows that STC1 may regulate CGRP and CT signaling
during osteoblastogenesis although the physiological conse-
quences of these remain to be elucidated.
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